BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30954941)

  • 21. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
    Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors.
    Timmermand OV; Nilsson J; Strand SE; Elgqvist J
    Med Phys; 2016 Dec; 43(12):6632. PubMed ID: 27908170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
    Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
    Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiolabeling, biodistribution, and dosimetry of (123)I-mAb 14C5: a new mAb for radioimmunodetection of tumor growth and metastasis in vivo.
    Lahorte CM; Bacher K; Burvenich I; Coene ED; Cuvelier C; De Potter C; Thierens H; Van de Wiele C; Dierckx RA; Slegers G
    J Nucl Med; 2004 Jun; 45(6):1065-73. PubMed ID: 15181142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
    Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
    J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
    Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
    Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of lipid-soluble complexes in targeted tumor therapy.
    Thakur ML; Coss R; Howell R; Vassileva-Belnikolovska D; Liu J; Rao SP; Spana G; Wachsberger P; Leeper DL
    J Nucl Med; 2003 Aug; 44(8):1293-300. PubMed ID: 12902421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First Evaluation of PET-Based Human Biodistribution and Dosimetry of
    Savi A; Incerti E; Fallanca F; Bettinardi V; Rossetti F; Monterisi C; Compierchio A; Negri G; Zannini P; Gianolli L; Picchio M
    J Nucl Med; 2017 Aug; 58(8):1224-1229. PubMed ID: 28209906
    [No Abstract]   [Full Text] [Related]  

  • 33. Quantitative PET Imaging of Tissue Factor Expression Using 18F-Labeled Active Site-Inhibited Factor VII.
    Nielsen CH; Erlandsson M; Jeppesen TE; Jensen MM; Kristensen LK; Madsen J; Petersen LC; Kjaer A
    J Nucl Med; 2016 Jan; 57(1):89-95. PubMed ID: 26383146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A compartmental model of mouse thrombopoiesis and erythropoiesis to predict bone marrow toxicity after internal irradiation.
    Sas N; Rousseau J; Nguyen F; Bellec E; Larrsson E; Becavin S; Hindorf C; Abadie J; Chouin N; Barbet J
    J Nucl Med; 2014 Aug; 55(8):1355-60. PubMed ID: 24935991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 4-Step renal dosimetry dependent on cortex geometry applied to 90Y peptide receptor radiotherapy: evaluation using a fillable kidney phantom imaged by 90Y PET.
    Walrand S; Jamar F; van Elmbt L; Lhommel R; Bekonde EB; Pauwels S
    J Nucl Med; 2010 Dec; 51(12):1969-73. PubMed ID: 21078802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
    Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
    J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite.
    Fisher DR; Fidel J; Maitz CA
    Cancer Biother Radiopharm; 2020 Feb; 35(1):1-9. PubMed ID: 31621382
    [No Abstract]   [Full Text] [Related]  

  • 38. Variation of Specific Activities of 68Ga-Aquibeprin and 68Ga-Avebetrin Enables Selective PET Imaging of Different Expression Levels of Integrins α5β1 and αvβ3.
    Notni J; Steiger K; Hoffmann F; Reich D; Schwaiger M; Kessler H; Wester HJ
    J Nucl Med; 2016 Oct; 57(10):1618-1624. PubMed ID: 27151985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerenkov Luminescence Imaging for Radiation Dose Calculation of a ⁹⁰Y-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Lohrmann C; Zhang H; Thorek DL; Desai P; Zanzonico PB; O'Donoghue J; Irwin CP; Reiner T; Grimm J; Weber WA
    J Nucl Med; 2015 May; 56(5):805-11. PubMed ID: 25840974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proof of Therapeutic Efficacy of a
    Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
    J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.